Trial eligibility hampers severe asthma progress

Randomised controlled trials evaluating phenotype targeted biological therapies in severe asthma do not reflect real-world populations and are poorly generalisable to clinical practice, a new study shows. Comparing data for 342 severe asthma patients within the Wessex Severe Asthma Cohort (WSAC) against comprehensive trial eligibility criteria for 37 randomised controlled trials (RCTs) in severe asthma, ...